UPDATE: Needham On Axonics Price Target Cut: Firm Notes Disappointing Results Given EPS Beat But Revenue Miss & Believes 'COVID Surge Was The Primary Culprit'; Sees SNM Growth Slow To 14% With FDA Results Expected In 1H22 For Non-Rechargeable SNM Device